HIV+Hep in the News

;

Senate maintains HIV funding

by | Aug 9, 2024

“While disappointed that Congress will not be providing the necessary funding to really end HIV or hepatitis in the United States, given the severe budget constraints, what the Senate has proposed will allow existing programs to at least continue,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, in a statement. “Now, for the benefit of the country, it is up to the House to act in a responsible manner and fund the federal government at the necessary levels in a timely fashion.”

read more

An upcoming White House decision may jeopardize Americans’ access to life-saving drugs

by | Aug 9, 2024

Copay assistance is critical for many patients—including those with cancer, arthritis, hemophilia, multiple sclerosis, HIV and hepatitis—to afford their high copays, pointed out Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Once the copay assistance runs out, the patient goes to pick up their drug and they are slapped with a several thousand dollar bill. This is a surprise to them—they thought they were picking up their drug with no problem, but they later learned that the copay assistance the insurer was collecting was not counting and in order to pick up their drug, they need to come up with that money,” he explained.

read more

Senate Approps asks for more hepatitis work without pay raise

by | Aug 7, 2024

The CDC’s hepatitis division funding would stay at $43 million in the Senate bill and the CDC Opioid Related Infectious Disease program (ORIDP) would remain at $23 million. According to the HIV+Hepatitis Institute, the House bill also adds an additional $6 million for the ORIDP. “It’s a shame that the Senate did not increase the funding because they gave them more work to do,” Carl Schmid, director of the Institute, told Inside Health Policy.

read more

Senate maintains HIV funding in spending bill, in contrast to House

by | Aug 2, 2024

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, thanked Senate lawmakers for prioritizing the domestic response to HIV in a statement responding to their bipartisan vote Thursday (Aug. 1) to advance the bill. “However, given that the House version of the bill includes sizeable funding cuts, program eliminations, and divisive policy riders, we realize passage of this spending bill is far from reality. House Republicans must come to the table and support bills, such as this one, that can pass the Congress and be signed by the President,” Schmid said.

read more

Search

Pin It on Pinterest

Share This